In this study, using genetic and pharmacological methods, including an iPSC model of HCMV latency, we identified bone morphogenetic protein receptor type 2 (BMPR2) as having a critical role in the maintenance of HCMV latent infection by modulating TGFbeta signaling. Here, BMPR2 is linked to disease arising from reactivation of latent virus.